Literature DB >> 22552288

Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation.

Jessica E Hutti1, Adam D Pfefferle, Sean C Russell, Mayukh Sircar, Charles M Perou, Albert S Baldwin.   

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is one of the most commonly misregulated signaling pathways in human cancers, but its impact on the tumor microenvironment has not been considered as deeply as its autonomous impact on tumor cells. In this study, we show that NF-κB is activated by the two most common PI3K mutations, PIK3CA E545K and H1047R. We found that markers of NF-κB are most strongly upregulated under conditions of growth factor deprivation. Gene expression analysis conducted on cells deprived of growth factors identified the repertoire of genes altered by oncogenic PI3K mutations following growth factor deprivation. This gene set most closely correlated with gene signatures from claudin-low and basal-like breast tumors, subtypes frequently exhibiting constitutive PI3K/Akt activity. An NF-κB-dependent subset of genes driven by oncogenic PI3K mutations was also identified that encoded primarily secreted proteins, suggesting a paracrine role for this gene set. Interestingly, while NF-κB activated by oncogenes such as Ras and EGF receptor leads to cell-autonomous effects, abrogating NF-κB in PI3K-transformed cells did not decrease proliferation or induce apoptosis. However, conditioned media from PI3K mutant-expressing cells led to increased STAT3 activation in recipient THP-1 monocytes or normal epithelial cells in a NF-κB and interleukin-6-dependent manner. Together, our findings describe a PI3K-driven, NF-κB-dependent transcriptional profile that may play a critical role in promoting a microenvironment amenable to tumor progression. These data also indicate that NF-κB plays diverse roles downstream from different oncogenic signaling pathways. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552288      PMCID: PMC3541677          DOI: 10.1158/0008-5472.CAN-11-4141

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

3.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Authors:  Steven J Isakoff; Jeffrey A Engelman; Hanna Y Irie; Ji Luo; Saskia M Brachmann; Rachel V Pearline; Lewis C Cantley; Joan S Brugge
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Authors:  T S Finco; J K Westwick; J L Norris; A A Beg; C J Der; A S Baldwin
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

5.  Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.

Authors:  C K Galang; J García-Ramírez; P A Solski; J K Westwick; C J Der; N N Neznanov; R G Oshima; C A Hauser
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

Review 6.  NF-kappaB: linking inflammation and immunity to cancer development and progression.

Authors:  Michael Karin; Florian R Greten
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

7.  Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Authors:  Tsuneo Ikenoue; Fumihiko Kanai; Yohko Hikiba; Toshiyuki Obata; Yasuo Tanaka; Jun Imamura; Miki Ohta; Amarsanaa Jazag; Bayasi Guleng; Keisuke Tateishi; Yoshinari Asaoka; Masayuki Matsumura; Takao Kawabe; Masao Omata
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

Authors:  Sohye Kang; Andreas G Bader; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

9.  A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.

Authors:  Karl Ziegelbauer; Florian Gantner; Nicholas W Lukacs; Aaron Berlin; Kinji Fuchikami; Toshiro Niki; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Mina Ishimori; Hiroshi Komura; Toshiki Murata; Timothy Lowinger; Kevin B Bacon
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 10.  NF-kappaB and IKK as therapeutic targets in cancer.

Authors:  H J Kim; N Hawke; A S Baldwin
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

View more
  44 in total

1.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Authors:  Suresh Mohan; Robert Vander Broek; Sujay Shah; Danielle F Eytan; Matthew L Pierce; Sophie G Carlson; Jamie F Coupar; Jialing Zhang; Hui Cheng; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

Review 2.  PI3K: A Crucial Piece in the RAS Signaling Puzzle.

Authors:  Agata Adelajda Krygowska; Esther Castellano
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

3.  Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.

Authors:  Evan C Lien; Laura Ghisolfi; Renee C Geck; John M Asara; Alex Toker
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

4.  VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.

Authors:  Jing Zhang; Tao Wu; Jeremy Simon; Mamoru Takada; Ryoichi Saito; Cheng Fan; Xian-De Liu; Eric Jonasch; Ling Xie; Xian Chen; Xiaosai Yao; Bin Tean Teh; Patrick Tan; Xingnan Zheng; Mingjie Li; Cortney Lawrence; Jie Fan; Jiang Geng; Xijuan Liu; Lianxin Hu; Jun Wang; Chengheng Liao; Kai Hong; Giada Zurlo; Joel S Parker; J Todd Auman; Charles M Perou; W Kimryn Rathmell; William Y Kim; Marc W Kirschner; William G Kaelin; Albert S Baldwin; Qing Zhang
Journal:  Science       Date:  2018-07-20       Impact factor: 47.728

Review 5.  The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment.

Authors:  Pablo Lopez-Bergami; Gastón Barbero
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

6.  Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers.

Authors:  Rosalie Sears; Joe W Gray
Journal:  Cancer Discov       Date:  2017-02       Impact factor: 39.397

7.  Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.

Authors:  Clémence Thomas; Whitney Henry; Benjamin G Cuiffo; Anthony Y Collmann; Elisabetta Marangoni; Vanessa Benhamo; Manoj K Bhasin; Cheng Fan; Laetitia Fuhrmann; Albert S Baldwin; Charles Perou; Anne Vincent-Salomon; Alex Toker; Antoine E Karnoub
Journal:  Sci Signal       Date:  2017-02-21       Impact factor: 8.192

8.  Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts.

Authors:  Daichi Ota; Masashi Kanayama; Yutaka Matsui; Koyu Ito; Naoyoshi Maeda; Goro Kutomi; Koichi Hirata; Toshihiko Torigoe; Noriyuki Sato; Akinori Takaoka; Ann F Chambers; Junko Morimoto; Toshimitsu Uede
Journal:  J Mol Med (Berl)       Date:  2014-08-08       Impact factor: 4.599

9.  Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.

Authors:  Whitney S Henry; Tyler Laszewski; Tiffany Tsang; Francisco Beca; Andrew H Beck; Sandra S McAllister; Alex Toker
Journal:  Cancer Res       Date:  2016-12-09       Impact factor: 12.701

10.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors:  Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal:  Eur J Cancer       Date:  2015-07-31       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.